Abstract | PURPOSE: A quality improvement project was implemented to improve adherence to evidence-based antiemetic guidelines for malignant glioma patients treated with moderately emetic chemotherapy (MEC). Poorly controlled chemotherapy-induced nausea and vomiting (CINV) reduce cancer treatment efficacy and significantly impair cancer patients' quality of life (QOL). A review of Duke University Preston Robert Tisch Brain Tumor Center (PRTBTC)'s usual practice demonstrates a high incidence (45%) of CINV, despite premedication with short-acting 5-HT3-serotonin-receptor antagonists (5-HT3-RAs). National Comprehensive Cancer Network (NCCN)'s evidence-based guidelines recommend the combination of the long-acting 5-HT3-RA palonosetron (PAL) and dexamethasone (DEX) for the prevention of acute and delayed CINV with MEC. Low adherence (58%) to antiemetic guidelines may have explained our high CINV incidence. METHODS: One-sample binomial test, quasi-experimental design, evaluated a combination intervention that included a provider education session; implementation of risk-assessment tool with computerized, standardized antiemetic guideline order sets; and a monthly audit-feedback strategy. Post-implementation adherence to evidence-based antiemetic order sets and patient outcomes were measured and compared to baseline and historical data. Primary outcome was the guideline order set adherence rate. Secondary outcomes included nausea/ vomiting rates and QOL. RESULTS: Adherence to ordering MEC guideline antiemetics increased significantly, from 58% to a sustained 90%, with associated improvement in nausea/ vomiting. In acute and delayed phases, 75 and 84% of patients, respectively, did not experience CINV. There was no significant change in QOL. CONCLUSION: Combination intervention and audit-feedback strategy to translate evidence into oncology practice improved and sustained adherence to antiemetic guidelines. Adherence corresponded with effective nausea/ vomiting control and preserved QOL in patients with malignant gliomas.
|
Authors | Mary Lou Affronti, Susan M Schneider, James E Herndon 2nd, Susan Schlundt, Henry S Friedman |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 22
Issue 7
Pg. 1897-905
(Jul 2014)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 24570103
(Publication Type: Journal Article)
|
Chemical References |
- Antiemetics
- Antineoplastic Agents
- Isoquinolines
- Quinuclidines
- Serotonin 5-HT3 Receptor Antagonists
- Palonosetron
- Dexamethasone
|
Topics |
- Adult
- Antiemetics
(administration & dosage)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Brain Neoplasms
(drug therapy)
- Dexamethasone
(administration & dosage)
- Female
- Glioblastoma
(drug therapy)
- Humans
- Isoquinolines
(administration & dosage)
- Male
- Medication Adherence
- Middle Aged
- Nausea
(chemically induced, drug therapy, prevention & control)
- Neoplasms
(drug therapy)
- Palonosetron
- Quality of Life
- Quinuclidines
(administration & dosage)
- Serotonin 5-HT3 Receptor Antagonists
(administration & dosage)
- Translational Research, Biomedical
- Treatment Outcome
- Vomiting
(chemically induced, drug therapy, prevention & control)
|